Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Canaccord Presentation

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Aug 27, 2021 2:24pm

110 Views

Post# 33776581

RE:Canaccord Presentation

EbbFlow88 wrote: Was anyone able to tune into this presentation? The press release mentioned they will make it available on the website but it doesn't seem to be uploaded.

I think it was only the presentation that was going to be made available - not the actual video from the conference call.

"A copy of the investor presentation will be available at www.gud-knight.com."

The presentation was then updated again 9 days after Canaccord.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle